Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

FLORIN A GAIDICI

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1780686147
CMS profile
353662
Location
PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$1,771.29

81 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,771.29 81

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

FLORIN A GAIDICI

NPI 1780686147 · CMS profile ID 353662

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1780686147?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
FLORIN A GAIDICI, NPI 1780686147, CMS profile ID 353662. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1780686147?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). FLORIN A GAIDICI, NPI 1780686147, CMS profile ID 353662. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1780686147?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
FLORIN A GAIDICI, NPI 1780686147, CMS profile ID 353662, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1780686147?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

81 matching records · $1,771.29 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 81 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–81 of 81.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $16.3205/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929458877 CMS
Ironwood Pharmaceuticals, Inc $19.6504/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957922841 CMS
Echosens North America, Inc. $132.2604/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 877936211 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $13.5804/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959483367 CMS
Gilead Sciences, Inc. $19.3304/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929458889 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.6104/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959477247 CMS
ABBVIE INC. $20.7304/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890996183 CMS
INTRA-SANA LABORATORIES $15.3104/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 964116019 CMS
Janssen Biotech, Inc. $18.6404/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885513127 CMS
Merck Sharp & Dohme LLC $18.9703/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944141525 CMS
Janssen Biotech, Inc. $16.3403/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885513133 CMS
Janssen Biotech, Inc. $2.2003/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885513139 CMS
Paratek Pharmaceuticals, Inc. $23.4803/17/2022 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 881646687 CMS
Gilead Sciences, Inc. $16.0703/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929458871 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $9.2903/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959840961 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $13.2803/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959388937 CMS
Takeda Pharmaceuticals U.S.A., Inc. $12.5603/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955639627 CMS
Alexion Pharmaceuticals, Inc. $11.8403/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915023741 CMS
Merck Sharp & Dohme LLC $18.8902/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944314077 CMS
Janssen Biotech, Inc. $20.6402/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885513121 CMS
RedHill Biopharma Inc. $11.7902/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902940899 CMS
Gilead Sciences, Inc. $119.4002/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929458913 CMS
Gilead Sciences, Inc. $23.2102/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929458907 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $22.2002/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959497881 CMS
ABBVIE INC. $25.4902/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890996181 CMS
Gilead Sciences, Inc. $9.1801/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929458865 CMS
Merck Sharp & Dohme LLC $20.7101/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944092941 CMS
Janssen Biotech, Inc. $18.7201/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885513167 CMS
Paratek Pharmaceuticals, Inc. $16.2901/13/2022 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 881646681 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $13.0101/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959591589 CMS
ABBVIE INC. $14.0401/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890996179 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,202.81 71
PY2020 $882.96 54
PY2021 $1,479.59 90
PY2022 $1,771.29 81
PY2023 $1,871.65 91
PY2024 $1,084.74 49
PY2025 $1,446.03 65

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $328,111.87 141
PY2024 Principal investigator $117,186.00 55
PY2023 Principal investigator $150,874.50 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

141 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $105.00 12/19/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223289986
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $420.00 12/19/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223289988
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $140.00 12/19/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223289990
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $56.00 12/19/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223289992
Principal investigator 1 SANOFI US SERVICES INC. $23,500.00 12/04/2025 Non-covered Recipient Entity
One Of A Kind Clinical Research
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226108199
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,435.00 10/15/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223286795
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $820.00 10/15/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223286797
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $552.00 10/15/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223286799
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $552.00 10/15/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223286801
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $552.00 10/15/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223286803
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,435.00 10/15/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223286833
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $820.00 10/15/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223286835
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $552.00 10/15/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223286837
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,435.00 10/15/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223286839
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $820.00 10/15/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223286841
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $552.00 10/15/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223286843
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $900.00 10/02/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223286219
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $630.00 10/02/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223286221
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $140.00 10/02/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223286223
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,000.00 10/02/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223286225
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,977.05 10/02/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223286227
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 10/02/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223286229
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $105.00 09/22/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223285780
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $210.00 09/22/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223285782
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $280.00 09/22/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223285784
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $56.00 09/22/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223285786
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $111.08 09/22/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223285788
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,435.00 09/17/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223285524
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $420.00 09/03/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223284819
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $315.00 09/03/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223284821
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $900.00 09/03/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223284823
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $630.00 09/03/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223284825
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $700.00 09/03/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223284827
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $420.00 09/03/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223284829
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $56.00 09/03/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223284831
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $630.61 09/03/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223284857
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,435.00 08/11/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223284013
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,043.00 08/11/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223284033
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $820.00 08/11/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223284035
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,043.00 08/11/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223284037
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,043.00 08/11/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223284061
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,043.00 07/16/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282632
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,043.00 07/16/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282634
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,043.00 07/16/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282636
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $19,824.45 07/07/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282286
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10.50 07/07/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282306
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $16,386.00 07/07/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282308
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,043.00 06/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223281530
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,043.00 06/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223281532
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,043.00 06/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223281534
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,043.00 06/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223281536
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $280.00 05/23/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223280166
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $140.00 05/23/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223280168
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $750.00 05/23/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223280170
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 05/23/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223280172
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 05/23/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223280206
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $600.00 05/23/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223280208
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 05/23/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223280210
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 05/23/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223280212
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 05/23/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223280214
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,587.18 05/23/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223280216
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,350.00 05/23/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223280218
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,058.00 05/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279490
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,043.00 05/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279492
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,043.00 05/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279494
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,043.00 05/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279496
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,043.00 05/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279566
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,043.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278234
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,754.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278236
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,043.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278238
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,009.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278240
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,365.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278242
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,009.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278244
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,365.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278246
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,043.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278248
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,754.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278250
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,043.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278252
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,009.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278254
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,365.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278256
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,009.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278258
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,365.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278274
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,043.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278276
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,754.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278278
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,043.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278374
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,009.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278376
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,365.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278378
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,009.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278380
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,365.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278382
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,043.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278384
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $854.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278386
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,754.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278388
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,043.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278390
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,009.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278392
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,365.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278394
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,009.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278396
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,365.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278398
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,043.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278400
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,754.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278402
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,043.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278404
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,009.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278438
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,365.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278440
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,009.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278442
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,365.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278444
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,043.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278446
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $854.00 04/18/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278448
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,124.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276507
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $854.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276509
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,509.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276511
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,614.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276513
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $764.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276515
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,409.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276517
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $764.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276519
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,514.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276521
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,124.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276523
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $764.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276525
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,514.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276527
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,124.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276529
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $854.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276531
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,124.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276533
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,058.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276549
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,058.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276551
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,509.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276553
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,614.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276555
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $764.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276557
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,409.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276559
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $764.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276561
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,514.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276563
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,124.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276565
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,509.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276567
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,614.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276569
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $764.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276571
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,409.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276573
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $764.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276575
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,514.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276577
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,124.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276581
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,058.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276617
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,058.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276619
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,058.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276621
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,058.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276623
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,058.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276625
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,058.00 03/14/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276627